Why Are Peptides Banned in Sport?

Peptides are banned in sport because many of them are growth factors, hormones or hormone-releasing agents — substances that could plausibly affect how an athlete performs or recovers — and because anti-doping rules are written by category rather than by naming every compound one at a time. A rule that lists individual names is out of date the moment a new analogue appears. So the prohibited list describes classes of substance and effect, and a compound that falls inside a class is prohibited whether or not anyone has written its name down.

That single design decision explains most of what people find confusing here: why obscure research compounds are covered, why “it isn’t on the list” is not a defence, and why a substance can be prohibited without anyone having shown that it does very much at all.

Which peptides are banned?

The honest answer is by category rather than by list, because categories are what the rules actually use. The prohibited classes most relevant to peptides are growth hormone together with its releasing factors and secretagogues, the growth factors that act on muscle and connective tissue, and the peptide hormones governing other endocrine axes 34.

• Growth hormone itself, along with its releasing factors and the secretagogues that prompt the pituitary to release more of it.
• Growth factors acting on muscle, tendon, ligament, blood vessel or connective tissue — anything with a plausible route to building or repairing tissue.
• Peptide hormones that raise red blood cell production, and the agents that mimic or stabilise the signals controlling it.
• Hormones and analogues acting on the gonadal, adrenal and metabolic axes.
• Modulators of the receptors and pathways those hormones act through, where the downstream effect would be similar.

Notice what those descriptions have in common: not one of them is a name. A class-based rule catches compounds nobody has named yet. If a laboratory publishes a novel fragment tomorrow that releases growth hormone, it is prohibited the day it exists, because the rule was written about what a substance does rather than about what it is called.

The names that do appear alongside each category are examples, not boundaries. They are almost always followed by wording to the effect of “and other substances with similar chemical structure or similar biological effect”. That phrase is doing more work than the list above it.

Does banned mean it works?

No, and this deserves saying plainly rather than in a footnote. A substance is prohibited when there is a plausible mechanism by which it could enhance performance, when it carries a potential health risk, or when it violates the spirit of sport — and meeting two of those three is enough. Demonstrated performance benefit in humans is not one of the requirements, and for several prohibited peptides that evidence does not exist.

Growth hormone is the clearest illustration, because it has been prohibited for decades and studied for almost as long. It reliably changes body composition and increases lean mass, but a substantial part of that increase is fluid, and controlled work in trained healthy adults has struggled to show matching gains in strength, power or endurance 34. That is not an argument for reclassifying it. It is an argument for being honest that the ban and the evidence are answering two different questions.

Intent is the other half of it. Anti-doping bodies are not only regulating substances that work; they are regulating the attempt. Someone who obtains a compound in order to gain an advantage has done the thing the rules exist to prevent, whether or not the pharmacology cooperated. This is why “it turned out to be useless” has never been a defence, and why the marketing around research peptides — which routinely promises far more than published human data supports — has no bearing on whether a compound is prohibited.

So read a prohibition as a statement about category and risk, never as a product endorsement in reverse. Plenty of people draw exactly that inference — if the authorities bothered to ban it, it must be potent — and it is among the least reliable arguments in this field.

Why is it hard to test for peptides?

Because a peptide given to a person often closely resembles, or is chemically identical to, something that person already produces. That is the central analytical problem, and it is a different kind of problem from the one posed by most other doping agents 1.

A conventional small-molecule drug is foreign. It has no natural counterpart in human plasma, so finding any of it at all is the finding. A recombinant human peptide with the same sequence as the endogenous one offers no such signal. The laboratory is not asking “is this present?” but “is there more of this than there should be, or a different mix of forms than the body makes on its own?” That is a much harder question, which is why detection strategies for this class are built around ratios, patterns and reference ranges rather than simple presence 13.

Two further properties compound the difficulty. Concentrations are extremely low — these are signalling molecules that act at a tiny fraction of the concentration of ordinary drugs, and the method has to reach down to that level inside a sample crowded with vastly more abundant proteins. And peptides clear quickly: they are cut apart by peptidases, filtered and metabolised, so the intact parent compound may be measurable only briefly 12. Analytical chemistry has answered this with progressively more sensitive mass spectrometry, immunoaffinity enrichment to pull a target out of a complex matrix, and detection of characteristic fragments rather than the whole molecule 2.

One thing this article will not do is turn any of that into practical detail. Fast clearance is a genuine analytical constraint, and people frequently arrive at it wanting a number — how long is something detectable for. We do not publish detection windows, rankings of which compounds evade which assays, or anything else that would function as guidance for passing a test. If that is the question, this is not the article — and the strategy behind it is a poor bet anyway, since stored samples are routinely reanalysed years later using methods that did not exist when the sample was given.

How do they test for growth hormone then?

Two approaches, used alongside each other. The first is the isoform method: the pituitary secretes growth hormone as a mixture of molecular forms of different sizes, whereas a recombinant preparation consists of a single form. Introducing that single form dilutes the natural mixture and shifts the ratio between forms into a pattern the body does not produce by itself. The test measures the ratio, not the total 34.

The second is the biomarker method. Instead of looking for the hormone, it measures what the hormone causes downstream — markers of the insulin-like growth factor axis and of bone and collagen turnover — and compares them against the range expected for an athlete of that age and sex. These markers respond more slowly than the hormone and persist longer, so the two approaches cover different periods and fail in different ways 4. Neither is sufficient alone; the case for running both is that the combination is much harder to be wrong about in either direction.

Both illustrate the general principle for peptides. Where you cannot detect the substance, you detect the disturbance it leaves behind.

Does “research use only” exempt an athlete?

No. Anti-doping rules attach to the substance found in the athlete’s body, not to how the container was labelled when it was bought.

“Research use only” is a supply-side classification. It describes the terms on which a chemical may lawfully be sold and what the seller is explicitly not claiming: that it is not an approved medicine, has not been assessed for human use, and is intended for laboratory work. It says nothing whatever about the molecule. A prohibited growth factor is the same growth factor regardless of which kind of vial it arrived in.

The neighbouring arguments fail for the same reason — that the substance was a peptide rather than a drug, that it was purchased legally, that no clinician was involved. None of them engages with the rule. Under strict liability an athlete is responsible for what is in their own sample, and the route by which it got there can affect the sanction at most, not whether a violation occurred.

What about a compound that isn’t on the list?

Absence from a named list is not the same as permission. The prohibited list carries catch-all provisions precisely so that “this specific name is not written down” does not resolve to “therefore it is allowed”.

There are two mechanisms. The first is the similar-structure-or-similar-biological-effect wording attached to most categories, which pulls in analogues and novel compounds that behave like the named examples. The second is the category covering substances with no current approval by any governmental regulatory health authority for human therapeutic use — compounds still in preclinical or clinical development, compounds discontinued, and compounds approved only for veterinary use. Most research peptides sit squarely inside that description, which is among the least appreciated facts in this whole area.

Put the two together and the practical position inverts the intuitive one. The question is not “is it named?” but “can this be shown to fall outside every class and every catch-all?” For an unapproved compound with unclear pharmacology, that is rarely a question with a comfortable answer. It is why anti-doping organisations tell athletes to check a substance before use rather than after, and why “I looked and did not see it” has failed as an argument many times over.

So what is the honest summary?

Peptides are prohibited in sport because they fall inside classes the rules were built to cover — hormones, growth factors and the agents that release them — and because those classes are defined by what a substance does rather than by an inventory of names.

Three things follow, and they are worth keeping separate. Prohibition is not evidence of efficacy: several prohibited peptides have little or no human data showing performance benefit, and appearing in a rulebook is not a claim that something works. Testing is genuinely difficult, because the analyte frequently resembles or matches something the body already makes, sits at very low concentration and clears fast 12 — which is why the successful methods measure ratios and downstream effects instead of presence 34. And none of the usual escape hatches hold: not the wording on the label, not the absence of a name from a list, not the thinness of the evidence.

For a researcher, the upshot is narrow and clear. These are prohibited classes of compound in competitive sport, most are not approved medicines anywhere, and material sold for laboratory work is sold for laboratory work. Anyone actually subject to anti-doping rules who finds themselves asking these questions should be asking their own anti-doping authority, in advance and in writing, rather than reading around the subject online.